Retraction notice to “Hypoxia induced E-cadherin involving regulators of Hippo pathway due to HIF-1α stabilization/nuclear translocation in bone metastasis from breast carcinoma” [Exp. Cell Res. 330 (2015) 287–299] (Experimental Cell Research (2015) 330(2) (287–299), (S0014482714004431), (10.1016/j.yexcr.2014.10.004));Hypoxia induced E-cadherin involving regulators of Hippo pathway due to HIF-1α stabilization/nuclear translocation in bone metastasis from breast carcinoma

Experimental Cell Research

Volumn 330, Issue 2, 2015, Pages 287-299

  Maroni, Paola ^a   Matteucci, Emanuela ^b   Drago, Lorenzo ^a,b   Banfi, Giuseppe ^a,b   Bendinelli, Paola ^b   Desiderio, Maria Alfonsina ^b  

^a IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Bone metastasis; E cadherin; HIF 1; Hypoxia; Wwox

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; ONCOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN MDM2; PROTEIN TAZ; PROTEIN WWOX; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; HIF1A PROTEIN, HUMAN; HIPPO PROTEIN, HUMAN; MDM2 PROTEIN, HUMAN; OXIDOREDUCTASE; PROTEIN SERINE THREONINE KINASE; TAZ PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; WWOX PROTEIN, HUMAN;

ARTICLE; BIOACCUMULATION; BONE METASTASIS; BREAST CARCINOMA; CELL HYPOXIA; CELL NUCLEUS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSFECTION; HALF LIFE TIME; HUMAN; HUMAN TISSUE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE; OXYGEN TENSION; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; TRANSACTIVATION; WWOX GENE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BONE TUMOR; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; PHYSIOLOGY; SECONDARY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

BONE NEOPLASMS; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; CELL HYPOXIA; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; OXIDOREDUCTASES; PPAR GAMMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84919796463     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2020.112164     Document Type: Erratum

References (46)

1. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transition in development and disease. Cell 2009, 139:871-890.
2. Zheng H., Kang Y. Multilayer control of the EMT master regulators. Oncogene 2014, 33:1755-1763.
3. Gall T.M.H., Frampton A.E. Gene of the month: E-cadherin (CDH1). J. Clin. Pathol. 2013, 66:928-932.
4. Paoli P., Giannoni E., Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim. Biophys. Acta 2013, 1833:3481-3498.
5. Matteucci E., Maroni P., Luzzati A., Perrucchini G., Bendinelli P., Desiderio M.A. Bone metastatic process of breast cancer involves methylation state affecting E-cadherin expression through TAZ and WWOX nuclear effectors. Eur. J. Cancer 2013, 49:231-244.
6. Berx G., van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 2001, 3:289-293.
7. Tsuji T., Ibaragi S., Hu G. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res. 2009, 69:7135-7139.
8. Chao Y.L., Shepard C.R., Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol. Cancer. 2010, 9:179-197.
9. Van der Pluijm G. Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 2011, 48:37-43.
10. Maroni P., Matteucci E., Luzzati A., Perrucchini G., Bendinelli P., Desiderio M.A. Nuclear co-localization and functional interaction of COX2 and HIF-1α characterize bone metastasis of human breast carcinoma. Breast Cancer Res. Treat. 2011, 129:433-450.
11. Mbalaviele G., Dunstan C.R., Sasaki A., Williams P.J., Mundy G.R., Yoneda T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res. 1996, 56:4063-4070.
12. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 2011, 11:411-425.
13. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordòn-Cardo C., Guise T.A., Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
14. Esteban M.A., Tran M.G., Harten S.K., Hill P., Castellanos M.C., Chandra A., Raval R., O'brien T.S., Maxwell P.H. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res. 2006, 66:3567-3575.
15. Imai T., Horiuchi A., Wang C., Oka K., Ohira S., Nikaido T., Konishi I. Hypoxia attenuates the expression of E-cadherin via upregulation of SNAIL in ovarian carcinoma cells. Am. J. Pathol. 2003, 163:1437-1447.
16. Finger E.C., Giaccia A.J. Hypoxia, inflammation and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev. 2010, 29:285-293.
17. Bendinelli P., Maroni P., Matteucci E., Luzzati A., Perrucchini.G., Desiderio M.A. Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer. Eur. J. Cancer 2013, 49:2608-2618.
18. Sudol M., Kieran F.H. Modularity in the Hippo signalling pathway. Trends Biochem. Sci. 2010, 35:627-633.
19. Matteucci E., Bendinelli P., Desiderio M.A. Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis 2009, 30:937-945.
20. Aqeilan R.I., Donati V., Gaudio E., Nicoloso M.S., Sundvall M., Korhonen A., Lundin J., Isola J., Sudol M., Joensuu H., Croce C.M., Elenius K. Association of Wwox with ErbB4 in breast cancer. Cancer Res. 2007, 67:9330-9336.
21. Salah Z., Aqeilan R., Huebner K. WWOX gene and gene product tumor suppression through specific protein interactions. Future Oncol. 2010, 6:249-259.
22. Chang J.-Y., He R.-Y., Lin H.-P., Hsu L.-J., Lai F.-J., Hong Q., Chen S.-J., Chang N.-S. Signaling from membrane receptors to tumor suppressor WW domain-containing oxidoreductase. Exp. Biol. Med. 2010, 235:796-804.
23. Suzuki H., Tomida A., Tsuruo T. Dephosphorylated hypoxia-inducible factor 1α as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 2001, 20:5779-5788.
24. Li M.-Y., Lai F.-J., Hsu L.-J., Lo C.-P., Cheng C.-L., Lin S.-R., Lee M.-H., Chang J.-Y., Subhan D., Tsai M.-S., Sze C.-I., Pugazhenthi S., Chang N.-S., Chen S.-T. Dramatic co-activation of WWOX/WOX1 with CREB and NF-kB in delayed loss of small dorsal root ganglion neurons upon sciatic nerve transaction in rats. PLoS One 2009, 4:e7820.
25. Dicitore A., Caraglia M., Gaudenzi G., Manfredi G., Amato B., Mari D., Persani L., Arra C., Vitale G. Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-road of pancreatic cancer cell proliferation. Biochim. Biophys. Acta 2014, 1845:42-52.
26. Chang J.-Y., He R.-Y., Lin H.-P., Hsu L.-J., Lai F.-J., Hong Q., Chen S.-J., Chang N.-S. Signaling from membrane receptors to tumor suppressor WW domain-containing oxidoreductase. Exp. Biol. Med. 2010, 235:796-804.
27. Jin C., Ge L., Ding X., Chen Y., Zhu H., Ward T., Wu F., Cao X., Wang Q., Yao X. PKA-mediated protein phosphorylation regulates ezrin-WWOX interaction. Biochem. Biophys. Res. Commun. 2006, 341:784-791.
28. Bendinelli P., Matteucci E., Maroni P., Desiderio M.A. NF-kB activation, dependent on acetylation/deacetylation, contributes to HIF-1 activity and migration of bone metastatic breast carcinoma cells. Mol. Cancer Res. 2009, 7:1328-1341.
29. Kowalczyk A.P., Nanes B.A. Adherens junction turnover: regulating adhesion through cadherin endocytosis, degradation, and recycling. Adherens Junctions: From Molecular Mechanisms to Tissue Development and Disease. Series: Subcellular Biochemistry 60 2012, 197-222. Springer Science- Business Media, Dordrecht, The Netherlands, (chap 9). T. Harris (Ed.).
30. Dang C.V., Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 1999, 24:68-72.
31. Gilkes D.M., Semenza G.L., Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat. Rev. Cancer 2014, 14:430-439.
32. Wang T., Gilkes D.M., Takano N., Xiang L., Luo W., Bishop C.J., Chaturvedi P., Green J.J., Semenza G.L. Hypoxia-inducible factors and RAB22A mediate formation of microvescicles that stimulate breast cancer invasion and metastasis. Proc. Natl. Acad. Sci. U.S.A 2014, 111:E3234-E3242.
33. Richard D.E., Berra E., Gothié E., Roux D., Pouysségur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 1999, 274:32631-32637.
34. Maroni P., Bendinelli P., Matteucci E., Locatelli A., Nakamura T., Scita G., Desiderio M.A. Osteolytic bone metastasis is hampered by impinging on the interplay among autophagy, anoikis and ossification. Cell Death Dis. 2014, 5:e1005.
35. Gunasinghe N.P., Wells A., Thompson E.W., Hugo H.J. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonization in breast cancer. Cancer Metastasis Rev. 2012, 31:468-478.
36. Bendinelli P., Maroni P., Matteucci E., Luzzati A., Perrucchini G., Desiderio M.A. Microenvironmental stimuli affect Endothelin-1 signaling responsible for invasiveness and osteomimicry of bone metastasis from breast cancer. Biochim. Biophys. Acta 2014, 1943:815-826.
37. Lowery F.J., Yu D. Growth factor signaling in metastasis: current understanding and future opportunities. Cancer Metastasis Rev. 2012, 31:479-491.
38. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009, 28:15-33.
39. Canel M., Serrels A., Frame M.C., Brunton V.G. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J. Cell Sci. 2013, 126:393-401.
40. Weber C.E., Kuo P.C. The tumor microenvironment. Surg. Oncol. 2012, 21:172-177.
41. Ludes-Meyers J.H., Bednarek A.K., Popescu N.C., Bedford M., Aldaz C.M. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet. Genome Res. 2003, 100:101-110.
42. Geng H., Liu Q., Xue C., David L.L., Beer T.M., Thomas G.V., Dai M.-S., Qian D.Z. HIF-1α stability is increased by acetylation at lysine 709. J. Biol. Chem 2012, 287:35496-35505.
43. Yu F.X., Mo J.-S., Guan K.L. Upstream regulators of the Hippo pathway. Cell Cycle 2012, 11:1-2.
44. Qin L., Gong C., Chen A.M., Guo F.J., Xu F., Ren Y., Liao H. Peroxisome proliferator-activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis. Mol. Med. Rep. 2014, 10:695-700.
45. Warfel N.A., Dolloff N.G., Dicker D.T., Malysz J., El-Deiry W.S. CDK1 stabilizes HIF-1α via direct phesphorylation of Ser668 to promote tumor growth. Cell Cycle 2013, 12:3689-3701.
46. Gilkes D.M., Semenza G.L. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol. 2013, 9:1623-1636.